Category: acquired thrombotic thrombocytopenic purpura

  • TargED Bio raises €39m for new clot-busting drug

    There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech – TargED Biopharmaceuticals – is hoping to disrupt the market with a new and improved therapy. It has just raised €39 million ($44 million) in first-round financing to help […]